Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial.
Antibiotics
Doxycycline
Open-label
PrEP
Prevention
Randomized controlled trial
STIs
Women’s health
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
16 Jun 2022
16 Jun 2022
Historique:
received:
04
02
2022
accepted:
09
06
2022
entrez:
16
6
2022
pubmed:
17
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Women in Africa face disproportionate risk of human immunodeficiency virus (HIV) acquisition, accounting for more than half of new infections in Africa and similarly face a disproportionate burden of sexually transmitted infections (STIs). Very high STI prevalence is being observed globally, especially among people taking pre-exposure prophylaxis (PrEP) for HIV prevention. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender men who have sex with men (MSM) and transgender women who are taking PrEP in high-income settings. We designed and describe here the first open-label trial to determine the effectiveness of dPEP to reduce STI incidence among cisgender women. We are conducting an open-label 1:1 randomized trial of dPEP versus standard of care (STI screening and treatment and risk-reduction counseling without dPEP) among 446 Kenyan women aged ≥ 18 and ≤ 30 years old women taking PrEP. Women are followed for 12 months, with quarterly STI testing, treatment, and adherence counseling. The primary trial outcome will be the combined incidence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, compared between the randomized groups. We will also assess dPEP acceptability, tolerability, safety, impact on sexual behavior, adherence, and occurrence of antimicrobial resistance (AMR) in N. gonorrhoeae and C. trachomatis isolates. Finally, we will estimate cost per incident STI case and complications averted accounting for nonadherence and benefits relative AMR or side effects. The results of this trial may have immediate implications for the global epidemic of STIs and sexual health. If effective, dPEP could put STI prevention into women's hands. While dPEP may be able to prevent STIs, it carries important risks that could counter its benefits; global debate about the balance of these potential risks and benefits requires data to inform policy and implementation and our study aims to fill this gap. ClinicalTrials.gov NCT04050540 .
Sections du résumé
BACKGROUND
BACKGROUND
Women in Africa face disproportionate risk of human immunodeficiency virus (HIV) acquisition, accounting for more than half of new infections in Africa and similarly face a disproportionate burden of sexually transmitted infections (STIs). Very high STI prevalence is being observed globally, especially among people taking pre-exposure prophylaxis (PrEP) for HIV prevention. Doxycycline post-exposure prophylaxis (dPEP) has been proposed as an STI prevention strategy to reduce chlamydia, syphilis, and possibly gonorrhea, and trials are ongoing among cisgender men who have sex with men (MSM) and transgender women who are taking PrEP in high-income settings. We designed and describe here the first open-label trial to determine the effectiveness of dPEP to reduce STI incidence among cisgender women.
METHODS
METHODS
We are conducting an open-label 1:1 randomized trial of dPEP versus standard of care (STI screening and treatment and risk-reduction counseling without dPEP) among 446 Kenyan women aged ≥ 18 and ≤ 30 years old women taking PrEP. Women are followed for 12 months, with quarterly STI testing, treatment, and adherence counseling. The primary trial outcome will be the combined incidence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, compared between the randomized groups. We will also assess dPEP acceptability, tolerability, safety, impact on sexual behavior, adherence, and occurrence of antimicrobial resistance (AMR) in N. gonorrhoeae and C. trachomatis isolates. Finally, we will estimate cost per incident STI case and complications averted accounting for nonadherence and benefits relative AMR or side effects.
DISCUSSION
CONCLUSIONS
The results of this trial may have immediate implications for the global epidemic of STIs and sexual health. If effective, dPEP could put STI prevention into women's hands. While dPEP may be able to prevent STIs, it carries important risks that could counter its benefits; global debate about the balance of these potential risks and benefits requires data to inform policy and implementation and our study aims to fill this gap.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04050540 .
Identifiants
pubmed: 35710444
doi: 10.1186/s13063-022-06458-8
pii: 10.1186/s13063-022-06458-8
pmc: PMC9201793
doi:
Substances chimiques
Doxycycline
N12000U13O
Banques de données
ClinicalTrials.gov
['NCT04050540']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495Subventions
Organisme : NIMH NIH HHS
ID : K23 MH124466
Pays : United States
Organisme : NIMH NIH HHS
ID : K23MH124466
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Antimicrob Agents Chemother. 2011 Aug;55(8):3882-8
pubmed: 21606224
Antimicrob Agents Chemother. 2004 Oct;48(10):3989-95
pubmed: 15388463
Sex Transm Infect. 2014 Mar;90(2):139-44
pubmed: 24154655
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3106-11
pubmed: 26976873
Int J STD AIDS. 2000 Dec;11(12):804-11
pubmed: 11138916
Ann N Y Acad Sci. 2019 Jan;1435(1):93-109
pubmed: 29876934
Microbiology (Reading). 2013 Apr;159(Pt 4):748-756
pubmed: 23378575
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
J Infect Dis. 2018 Jul 24;218(5):801-808
pubmed: 29701830
J Infect Chemother. 2014 Nov;20(11):709-15
pubmed: 25172777
Antibiotics (Basel). 2018 Jul 12;7(3):
pubmed: 30002329
AIDS. 2012 Jun 19;26(10):1205-13
pubmed: 22706007
AIDS. 2014 Mar;28 Suppl 2:S187-204
pubmed: 24849479
Gates Open Res. 2017 Nov 6;1:3
pubmed: 29355231
Gates Open Res. 2017 Dec 29;1:17
pubmed: 29355224
Infect Dis Obstet Gynecol. 2011;2011:525182
pubmed: 21949601
AIDS. 2020 Apr 1;34(5):651-658
pubmed: 32167988
Sex Transm Dis. 2015 Feb;42(2):104-6
pubmed: 25585070
Sex Transm Dis. 1999 Apr;26(4 Suppl):S12-20; discussion S21-2
pubmed: 10227695
Br J Obstet Gynaecol. 1991 Dec;98(12):1260-6
pubmed: 1777459
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
PLoS One. 2009 Jul 31;4(7):e6470
pubmed: 19649242
Euro Surveill. 2014 Aug 28;19(34):
pubmed: 25188611
Sex Transm Dis. 2012 May;39(5):332-4
pubmed: 22504591
N Engl J Med. 2016 Dec;375(22):2121-2132
pubmed: 26900902
Sex Transm Dis. 2015 Feb;42(2):98-103
pubmed: 25585069
Int J STD AIDS. 2016 Jan;27(1):19-24
pubmed: 25614522
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84
pubmed: 25761233
Am J Trop Med Hyg. 2011 Apr;84(4):517-31
pubmed: 21460003
PLoS One. 2015 Jan 20;10(1):e0116100
pubmed: 25602351
Science. 2018 May 18;360(6390):733-738
pubmed: 29773743
AIDS. 2015 Jun 1;29(9):1077-85
pubmed: 26125141
Hum Reprod Update. 1999 Sep-Oct;5(5):433-47
pubmed: 10582782
AIDS. 2012 Feb 20;26(4):437-45
pubmed: 22095197
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
PLoS One. 2012;7(5):e36797
pubmed: 22574226
N Engl J Med. 2014 Nov 6;371(19):1850-1
pubmed: 25372111
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Reprod Health Matters. 2003 Nov;11(22):74-90
pubmed: 14708399
Sex Transm Dis. 2011 Apr;38(4):329-33
pubmed: 21042234
J Int AIDS Soc. 2019 Feb;22(2):e25257
pubmed: 30816632
Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents
pubmed: 11381101
Ann Behav Med. 1998 Winter;20(1):25-30
pubmed: 9755348
N Engl J Med. 2001 Jul 12;345(2):79-84
pubmed: 11450675
Sex Transm Dis. 2016 Feb;43(2 Suppl 1):S3-7
pubmed: 26779686
AIDS Behav. 2017 Feb;21(2):481-491
pubmed: 27858268
Sex Transm Infect. 2006 Oct;82(5):386-91
pubmed: 17012514
Lancet Infect Dis. 2018 Mar;18(3):308-317
pubmed: 29229440
AIDS Educ Prev. 2018 Oct;30(5):357-368
pubmed: 30332308
JAMA. 2004 Jun 2;291(21):2555-62
pubmed: 15173146
Bull World Health Organ. 2009 Nov;87(11):858-65
pubmed: 20072772
AIDS. 2017 May 15;31(8):1159-1167
pubmed: 28441175
J Infect Dis. 2004 Apr 15;189(8):1497-505
pubmed: 15073688
AIDS Behav. 2017 May;21(5):1361-1375
pubmed: 27317411